• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Perioperative considerations for neoadjuvant immunotherapy in non-small cell lung cancer.

作者信息

Stiles Brendon M, Sepesi Boris, Broderick Stephen R, Bott Matthew J

机构信息

Division of Thoracic Surgery, Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY.

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Tex.

出版信息

J Thorac Cardiovasc Surg. 2020 Nov;160(5):1376-1382. doi: 10.1016/j.jtcvs.2020.05.119. Epub 2020 Jul 5.

DOI:10.1016/j.jtcvs.2020.05.119
PMID:32763029
Abstract
摘要

相似文献

1
Perioperative considerations for neoadjuvant immunotherapy in non-small cell lung cancer.非小细胞肺癌新辅助免疫治疗的围手术期注意事项
J Thorac Cardiovasc Surg. 2020 Nov;160(5):1376-1382. doi: 10.1016/j.jtcvs.2020.05.119. Epub 2020 Jul 5.
2
Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.新辅助纳武利尤单抗治疗可切除非小细胞肺癌患者肺切除术后的初步结果。
J Thorac Cardiovasc Surg. 2019 Jul;158(1):269-276. doi: 10.1016/j.jtcvs.2018.11.124. Epub 2018 Dec 13.
3
Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).术前 PD1 检查点阻断和核因子κB 受体激活剂配体（RANKL）抑制在非小细胞肺癌（NSCLC）中的药效学：一项多中心、开放标签、1B/2 期、转化试验（POPCORN）的研究方案。
Trials. 2019 Dec 19;20(1):753. doi: 10.1186/s13063-019-3951-x.
4
Integrated management of stage III in nonsmall cell lung cancer: where do perioperative chemotherapy and immunotherapy fit?Ⅲ期非小细胞肺癌的综合治疗：围手术期化疗和免疫治疗的地位如何？
Curr Opin Pulm Med. 2024 Jul 1;30(4):346-351. doi: 10.1097/MCP.0000000000001079. Epub 2024 May 7.
5
A banner year for immunotherapy and targeted therapy.免疫疗法和靶向疗法的丰收之年。
Nat Rev Clin Oncol. 2019 Feb;16(2):79-80. doi: 10.1038/s41571-018-0138-4.
6
Discussion to: Induction chemoimmunotherapy with surgery versus concurrent chemoradiation followed by immunotherapy for stage III-N2 non-small cell lung cancer.针对：III-N2期非小细胞肺癌，手术联合诱导化疗免疫疗法与同步放化疗后序贯免疫疗法的讨论。
J Thorac Cardiovasc Surg. 2024 Jun;167(6):1906-1907. doi: 10.1016/j.jtcvs.2023.10.035. Epub 2023 Nov 28.
7
Immunotherapy combinations emerging in non-small-cell lung cancer.非小细胞肺癌中出现的免疫疗法联合方案。
Immunotherapy. 2018 Jun;10(8):627-629. doi: 10.2217/imt-2018-0046.
8
KEYNOTE-024: Unlocking a pathway to lung cancer cure?KEYNOTE-024：开启肺癌治愈之路？
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1777-1780. doi: 10.1016/j.jtcvs.2017.10.155. Epub 2017 Dec 23.
9
Recent clinical trials of immunotherapy in non-small-cell lung cancer.近期非小细胞肺癌免疫疗法的临床试验。
Immunotherapy. 2019 Apr;11(6):461-466. doi: 10.2217/imt-2019-0021.
10
The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer.可切除非小细胞肺癌新辅助免疫治疗中的手术视角。
Cancer Immunol Immunother. 2021 Aug;70(8):2313-2321. doi: 10.1007/s00262-021-02847-1. Epub 2021 Jan 29.

引用本文的文献

1
Breast Cancer Immunotherapy: A Clinical Review for the Plastic Surgeon.乳腺癌免疫疗法：整形外科医生的临床综述
Plast Reconstr Surg Glob Open. 2024 Jun 18;12(6):e5915. doi: 10.1097/GOX.0000000000005915. eCollection 2024 Jun.
2
Minimally invasive surgery for clinical T4 non-small-cell lung cancer: national trends and outcomes.临床 T4 期非小细胞肺癌的微创外科治疗：国家趋势和结果。
Eur J Cardiothorac Surg. 2024 Mar 1;65(3). doi: 10.1093/ejcts/ezae009.
3
Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process.
加拿大可切除 II/III 期非小细胞肺癌管理共识推荐意见：一项改良 Delphi 流程的研究结果。
Curr Oncol. 2023 Dec 6;30(12):10363-10384. doi: 10.3390/curroncol30120755.
4
The beginning of the perioperative immunotherapy era in early-stage non-small cell lung cancer.早期非小细胞肺癌围手术期免疫治疗时代的开端。
Transl Lung Cancer Res. 2023 Nov 30;12(11):2359-2365. doi: 10.21037/tlcr-23-470. Epub 2023 Nov 1.
5
Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer.新辅助免疫检查点抑制剂在可切除非小细胞肺癌中的作用
Pharmaceuticals (Basel). 2023 Feb 3;16(2):233. doi: 10.3390/ph16020233.
6
Comprehensive F-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: A pilot study.基于 F-FDG PET 的全面放射组学在提升可切除 III 期非小细胞肺癌新辅助免疫化疗病理反应中的作用：一项初步研究。
Front Immunol. 2022 Nov 17;13:994917. doi: 10.3389/fimmu.2022.994917. eCollection 2022.
7
Cancer Immunotherapies: What the Perioperative Physician Needs to Know.癌症免疫疗法：围手术期医生需要了解的知识。
Curr Oncol Rep. 2022 Apr;24(4):399-414. doi: 10.1007/s11912-022-01202-6. Epub 2022 Feb 10.
8
Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial.非小细胞肺癌围手术期免疫治疗专家共识：一篇社论
Transl Lung Cancer Res. 2021 Dec;10(12):4322-4327. doi: 10.21037/tlcr-21-882.
9
Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review.新辅助靶向治疗后非小细胞肺癌手术的安全性：叙事性综述。
Int J Mol Sci. 2021 Nov 12;22(22):12244. doi: 10.3390/ijms222212244.
10
Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer.局部晚期可切除 III 期非小细胞肺癌新辅助替雷利珠单抗联合化疗的 II 期临床研究。
Oncoimmunology. 2021 Oct 25;10(1):1996000. doi: 10.1080/2162402X.2021.1996000. eCollection 2021.